Observational studyMedicine2025
Effect of pre-stroke statin use on the progression of intracranial atherosclerosis in ischemic stroke patients: Evidence from high-resolution magnetic resonance imaging.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-resolution magnetic resonance imaging (HR-MRI) has emerged as a valuable tool for evaluating intracranial atherosclerotic plaque characteristics in vivo. This study aimed to identify clinical and imaging predictors of plaque enhancement (PE) on HR-MRI in patients presenting with acute ischemic stroke (AIS) or transient ischemic attack (TIA). We retrospectively included consecutive patients diagnosed with AIS or TIA who underwent HR-MRI between January 2021 and August 2022. Participants were categorized according to the presence or absence of contrast enhancement in culprit plaques and further stratified by prior statin usage. Plaque enhancement was defined as increased signal intensity on contrast-enhanced T1-weighted images. Clinical profiles and imaging parameters were compared between groups. Among the 208 participants, 138 demonstrated enhancement of the culprit plaque, whereas 70 showed no such enhancement. Enhanced plaques were associated with significantly greater plaque burden and higher degrees of luminal stenosis (both P < .001). At the site of maximum stenosis, patients without enhancement exhibited significantly larger vessel area (VA; P = .01) and lumen area (LA; P < .001). A modest but statistically significant correlation was observed between stenosis severity and enhancement grade (Spearman ρ = 0.372, P < .001). Notably, prior use of statins was associated with a lower incidence of PE (P = .03). HR-MRI-detected PE is associated with more severe arterial narrowing and may serve as an indicator of plaque instability. The observed reduction in enhancement among statin users supports the potential role of statin therapy in stabilizing intracranial atherosclerotic lesions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.